JP2025515497A5 - - Google Patents

Info

Publication number
JP2025515497A5
JP2025515497A5 JP2024563644A JP2024563644A JP2025515497A5 JP 2025515497 A5 JP2025515497 A5 JP 2025515497A5 JP 2024563644 A JP2024563644 A JP 2024563644A JP 2024563644 A JP2024563644 A JP 2024563644A JP 2025515497 A5 JP2025515497 A5 JP 2025515497A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
fragment
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020351 external-priority patent/WO2023212293A1/en
Publication of JP2025515497A publication Critical patent/JP2025515497A/ja
Publication of JP2025515497A5 publication Critical patent/JP2025515497A5/ja
Pending legal-status Critical Current

Links

JP2024563644A 2022-04-29 2023-04-28 補体h因子関連4特異的抗体及びその使用 Pending JP2025515497A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336751P 2022-04-29 2022-04-29
US63/336,751 2022-04-29
PCT/US2023/020351 WO2023212293A1 (en) 2022-04-29 2023-04-28 Complement factor h related 4-specific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025515497A JP2025515497A (ja) 2025-05-15
JP2025515497A5 true JP2025515497A5 (cg-RX-API-DMAC7.html) 2026-05-12

Family

ID=86424821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563644A Pending JP2025515497A (ja) 2022-04-29 2023-04-28 補体h因子関連4特異的抗体及びその使用

Country Status (11)

Country Link
US (1) US20250289873A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514844A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515497A (cg-RX-API-DMAC7.html)
KR (1) KR20250021400A (cg-RX-API-DMAC7.html)
CN (1) CN119365485A (cg-RX-API-DMAC7.html)
AU (1) AU2023260822A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250483A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003283A1 (cg-RX-API-DMAC7.html)
IL (1) IL316610A (cg-RX-API-DMAC7.html)
MX (1) MX2024013188A (cg-RX-API-DMAC7.html)
WO (1) WO2023212293A1 (cg-RX-API-DMAC7.html)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
FR2785281B1 (fr) 1999-07-05 2001-04-27 Ugimag Sa Procede de fabrication de poudres ou biscuits d'hexaferrites de type m
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2016126747A1 (en) 2015-02-02 2016-08-11 Meiragtx Uk Limited Regulation of gene expression by aptamer-mediated modulation of alternative splicing
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
WO2019126222A1 (en) 2017-12-18 2019-06-27 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
US20210363192A1 (en) 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2019217483A1 (en) 2018-05-07 2019-11-14 Spark Therapeutics, Inc. Plasmid free aav vector producing cell lines
JP7467355B2 (ja) * 2018-05-10 2024-04-15 コンプリメント・セラピューティクス・リミテッド 黄斑変性症を評価するための方法
CA3119349A1 (en) 2018-11-16 2020-05-22 Spark Therapeutics, Inc. In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies

Similar Documents

Publication Publication Date Title
JP2025514437A5 (cg-RX-API-DMAC7.html)
US9416182B2 (en) Anti-TNF-anti-IL-17 bispecific antibodies
JP2021036888A (ja) 二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用
TWI890481B (zh) 雙特異性抗體
TW202241966A (zh) 對於介白素-4受體及介白素-31具特異性之多特異性抗體
JP2022122865A5 (cg-RX-API-DMAC7.html)
EP3581245A1 (en) Antibodies to tau and uses thereof
JP2021514670A5 (cg-RX-API-DMAC7.html)
JP2023534214A5 (cg-RX-API-DMAC7.html)
CN106565840A (zh) 抗乙肝表面抗原的抗体及其用途
JP2023130473A (ja) 眼又は眼疾患を処置するための抗セマフォリン3a抗体及びその使用
TW202515905A (zh) 用於遞送顆粒蛋白穿過血腦障壁之化合物
US20230406942A1 (en) Igf1r antibodies
JP2024523514A5 (cg-RX-API-DMAC7.html)
JP2025517111A5 (cg-RX-API-DMAC7.html)
JP2020534307A (ja) 抗体変異体
US20250122286A1 (en) Antibody optimization
JP2025525442A (ja) Ang2/vegf抗体およびその使用
JP2025503707A5 (cg-RX-API-DMAC7.html)
WO2023134771A1 (zh) 抗ctla-4抗体药物组合物及其用途
CN111108122B (zh) 抗体变体
AU2024354938A1 (en) Compostions of multispecific antigen binding polypeptides and methods of use
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
TW202313693A (zh) 一種cdc平臺抗體
JP2025094941A (ja) Lag-3アゴニスト抗体